Price range: $120.00 through $205.00
You save (%)
GLP-R is a novel 39-amino-acid triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. This triple agonist approach represents a new paradigm in metabolic research. Early studies have shown remarkable effects on body weight reduction and metabolic parameters, with Phase 2 trials demonstrating unprecedented efficacy in weight management research.
These products are for laboratory research only and not intended for medical use. They must be handled by qualified professionals in controlled laboratory environments. This compound has not been evaluated by the FDA and is not approved for human or veterinary use.
These products are for laboratory research only and not intended for medical use. Qualified professionals in controlled laboratory environments must handle them. The FDA has not evaluated this compound, and it is not approved for human or veterinary use.
Third-party tested for purity, identity, and quantity.
VL-9759917
GLP-R is supplied as a lyophilized (freeze-dried) white to off-white powder. Purity is ≥98% as determined by HPLC analysis, and the product is accompanied by a certificate of analysis (CoA) confirming identity by mass spectrometry. This material is intended exclusively for laboratory research use.
The lyophilized peptide should be stored at -20°C or below in a desiccated, dark environment. Once reconstituted, working solutions should be aliquoted to avoid repeated freeze-thaw cycles, stored at -80°C, and used within an appropriately validated timeframe. Stability data should be confirmed under each laboratory’s specific conditions.
For general in vitro research applications, the lyophilized peptide is commonly reconstituted in sterile water, phosphate-buffered saline (PBS), or aqueous buffers compatible with the experimental system. Researchers should prepare stock solutions at concentrations appropriate for their assay format and dilute further into cell culture media or buffer as required. Individual research protocols should be validated by the end-user laboratory.
Published preclinical research has employed diet-induced obese (DIO) mouse and rat models, receptor-transfected cell lines (e.g., HEK293 expressing GLP-1R, GIPR, and GCGR), isolated pancreatic islets, and primary hepatocyte cultures. Phase 1 and Phase 2 human clinical trials have also been published by the originating pharmaceutical sponsor; however, this product is supplied solely for laboratory and preclinical research contexts.
No. GLP-R supplied by this vendor is strictly for in vitro laboratory and preclinical research use only. It is not approved by the FDA or any regulatory authority for human administration, therapeutic application, or diagnostic use. It must not be used in humans or animals outside of formally approved research protocols.
GLP-R is a triagonist peptide designed to engage three G-protein-coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). Research interest centers on whether simultaneous activation of these three receptors produces additive or synergistic downstream effects on metabolic signaling, energy expenditure, and glucose homeostasis pathways compared to single- or dual-receptor agonists. This multi-target profile makes it a valuable compound for dissecting incretin and glucagon biology in laboratory models.
Scientific research has identified several key areas where GLP-R shows promising applications.
These research findings represent ongoing studies and should not be interpreted as medical claims or recommendations.
